Novel treatment of human pancreatic cancer xenografts with mimosine, a cell cycle regulator amino acid

Background: In recent years, several cell cycle checkpoint regulators, as potential anticancer drugs, are being evaluated, and some of these compounds are also tested in Phase I – II clinical trials. Among the cell synchronizing agents, mimosine, a plant-derived amino acid is known to block the cell cycle in late G1 phase. Based on encouraging in vitro studies we have treated human pancreatic cancer xenografts with mimosine. Materials and Methods: Human ductal pancreatic carcinoma xenografts (PZX-40/8) growing in immunosuppressed mice have been treated with 30mg/kg b.w. L-mimosine subcutaneously for 34 days. Mim…